Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Pregnancy and Childbirth
Published in: BMC Pregnancy and Childbirth 1/2024

Open Access 01-12-2024 | Premature Birth | Research

Low-dose aspirin for the prevention of preterm birth in nulliparous women: systematic review and meta-analysis

Authors: Xin Yan, Wei Zheng, Jia Wang, Xianxian Yuan, Guanghui Li

Published in: BMC Pregnancy and Childbirth | Issue 1/2024

Login to get access

Abstract

Objective

The objective was to assess the efficacy and safety of low-dose aspirin for the prevention of preterm birth in nulliparous women.

Data sources

We searched PubMed, Embase and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception to June 2022.

Study eligibility criteria

Randomized controlled trials that compared aspirin to placebo in nulliparous women were eligible.

Methods

This study was reported in accordance with the PRISMA 2020 checklist. The primary outcomes of this study were the rates of preterm birth at less than 37 weeks and less than 34 weeks of gestation. The secondary outcomes included postpartum hemorrhage, placental abruption, cesarean section, any hypertensive disorder of pregnancy and small for gestational age. Relative risks with their 95% confidence intervals were calculated for analysis. Heterogeneity was assessed by Cochran’s Q test and Higgins’s I2. A random-effects model was used when I2 was > 50% to generate the RR and 95% CI; otherwise, a fixed-effects model was used. The risk of publication bias was assessed by funnel plots. We performed sensitivity analysis by sequentially omitting each included study to confirm the robustness of the analysis.

Results

Seven studies with a total of 29,029 participants were included in this review. Six studies were assessed as having a low risk of bias or an unclear risk of bias, and one study was judged as having a high risk of bias. In nulliparous women, low-dose aspirin was associated with a significant reduction in the rate of preterm birth at less than 34 weeks of gestational age (RR 0.84,95% CI: 0.71–0.99; I2 = 0%; P = 0.04), but we did not observe a significant difference in the rate of preterm birth at less than 37 weeks of gestation (RR 0.96,95% CI: 0.90–1.02; I2 = 31%; P = 0.18). Low-dose aspirin was associated with a significant increase in the rates of postpartum hemorrhage (RR 1.32,95% CI: 1.14–1.54; I2 = 0%; P = 0.0003), placental abruption (RR 2.18,95% CI: 1.10–4.32; I2 = 16%; P = 0.02) and cesarean section (RR 1.053, 95% CI: 1.001–1.108; I2 = 0%; P = 0.05) in nulliparous women. We also did not observe a significant effect of low-dose aspirin on the rates of any hypertensive disorder of pregnancy (RR 1.05, 95% CI: 0.96–1.14; I2 = 9%; P = 0.28) or small for gestational age (RR 0.96, 95% CI: 0.91–1.02; I2 = 0%; P = 0.16) in nulliparous women. Funnel plots indicated that no significant publication bias existed in this meta-analysis. Except for preterm birth at less than 34 weeks of gestation, placental abruption and cesarean section, the sensitivity analysis showed similar results, which confirmed the robustness of this meta-analysis.

Conclusions

Low-dose aspirin might reduce the risk of preterm birth at less than 34 weeks of gestation in nulliparous women. The use of low-dose aspirin in nulliparous women increased the risk of postpartum hemorrhage and might increase the risk of placental abruption and cesarean section.
Appendix
Available only for authorised users
Literature
1.
Goodfellow L, Care A, Alfirevic Z. Controversies in the prevention of spontaneous preterm birth in asymptomatic women: an evidence summary and expert opinion. BJOG. 2021;128(2):177–94.PubMedCrossRef
2.
Liu L, Oza S, Hogan D, Chu Y, Perin J, Zhu J, et al. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the Sustainable Development Goals. Lancet (London England). 2016;388(10063):3027–35.PubMedCrossRef
3.
4.
Rubens CE, Sadovsky Y, Muglia L, Gravett MG, Lackritz E, Gravett C. Prevention of preterm birth: harnessing science to address the global epidemic. Sci Transl Med. 2014;6(262):262sr5.PubMedCrossRef
5.
Harrison M, Goldenberg R. Global burden of prematurity. Semin Fetal Neonatal Med. 2016;21(2):74–9.PubMedCrossRef
6.
Breslin N, Gyamfi-Bannerman C. Current Preterm Birth Prevention Strategies. Clin Perinatol. 2020;47(4):705–17.PubMedCrossRef
7.
Matei A, Saccone G, Vogel JP, Armson AB. Primary and secondary prevention of preterm birth: a review of systematic reviews and ongoing randomized controlled trials. Eur J Obstet Gynecol Reprod Biol. 2019;236:224–39.PubMedCrossRef
8.
Medley N, Poljak B, Mammarella S, Alfirevic Z. Clinical guidelines for prevention and management of preterm birth: a systematic review. BJOG. 2018;125(11):1361–9.PubMedCrossRef
9.
Shennan AH. Prediction and prevention of preterm birth: a quagmire of evidence. Ultrasound Obstet Gynecol. 2018;51(5):569–70.PubMedCrossRef
10.
Martin J, DʼAlton M, Jacobsson B, Norman J. Pursuit of Progress toward Effective Preterm Birth reduction. Obstet Gynecol. 2017;129(4):715–9.PubMedCrossRef
11.
ACOG Committee Opinion No. 743: low-dose aspirin use during pregnancy. Obstet Gynecol. 2018;132(1):e44–52.CrossRef
12.
Rolnik DL, Nicolaides KH, Poon LC. Prevention of preeclampsia with aspirin. Am J Obstet Gynecol. 2022;226(2s):S1108–19.PubMedCrossRef
13.
LeFevre ML. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;161(11):819–26.PubMedCrossRef
14.
Hypertension in pregnancy. Report of the American College of Obstetricians and gynecologists’ Task Force on hypertension in pregnancy. Obstet Gynecol. 2013;122(5):1122–31.
15.
Organization WH. WHO Recommendations for Prevention and Treatment of Pre-eclampsia and Eclampsia. Clin Endocrinol. 2011;53(2):260–1.
16.
17.
Combs CA, Montgomery DM. Society for maternal-fetal Medicine Special Statement: checklists for preeclampsia risk-factor screening to guide recommendations for prophylactic low-dose aspirin. Am J Obstet Gynecol. 2020;223(3):B7–11.PubMedCrossRef
18.
Landman A, de Boer MA, Visser L, Nijman TAJ, Hemels MAC, Naaktgeboren CN, et al. Evaluation of low-dose aspirin in the prevention of recurrent spontaneous preterm labour (the APRIL study): a multicentre, randomised, double-blinded, placebo-controlled trial. PLoS Med. 2022;19(2):e1003892.PubMedPubMedCentralCrossRef
19.
20.
Davidson K, Barry M, Mangione C, Cabana M, Caughey A, Davis E, et al. Aspirin use to prevent Preeclampsia and related morbidity and mortality: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;326(12):1186–91.PubMedCrossRef
21.
Allshouse AA, Jessel RH, Heyborne KD. The impact of low-dose aspirin on preterm birth: secondary analysis of a randomized controlled trial. J Perinatol. 2016;36(6):427–31.PubMedCrossRef
22.
van Vliet EOG, Askie LA, Mol BWJ, Oudijk MA. Antiplatelet agents and the Prevention of spontaneous Preterm Birth: a systematic review and Meta-analysis. Obstet Gynecol. 2017;129(2):327–36.PubMedCrossRef
23.
Andrikopoulou M, Purisch SE, Handal-Orefice R, Gyamfi-Bannerman C. Low-dose aspirin is associated with reduced spontaneous preterm birth in nulliparous women. Am J Obstet Gynecol. 2018;219(4):399. e1-e6.CrossRef
24.
Hoffman MK, Goudar SS, Kodkany BS, Metgud M, Somannavar M, Okitawutshu J, et al. Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial. Lancet (London England). 2020;395(10220):285–93.PubMedCrossRef
25.
WHO Guidelines Approved by the Guidelines Review Committee. WHO Recommendations for the Prevention and Treatment of Postpartum Haemorrhage. Geneva: World Health Organization Copyright © 2012, World Health Organization.; 2012.
26.
Villar J, Cheikh Ismail L, Victora CG, Ohuma EO, Bertino E, Altman DG, et al. International standards for newborn weight, length, and head circumference by gestational age and sex: the newborn cross-sectional study of the INTERGROWTH-21st Project. Lancet. 2014;384(9946):857–68.PubMedCrossRef
27.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.PubMedPubMedCentralCrossRef
28.
Higgins JPTTJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. Chichester (UK): Wiley; 2019.
29.
30.
Higgins J, Thompson S, Deeks J, Altman D. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy. 2002;7(1):51–61.PubMedCrossRef
31.
32.
Mone F, Mulcahy C, McParland P, Breathnach F, Downey P, McCormack D, et al. Trial of feasibility and acceptability of routine low-dose aspirin versus early screening test indicated aspirin for pre-eclampsia prevention (TEST study): a multicentre randomised controlled trial. BMJ open. 2018;8(7):e022056.PubMedPubMedCentralCrossRef
33.
Bakhti A, Vaiman D. Prevention of gravidic endothelial hypertension by aspirin treatment administered from the 8th week of gestation. Hypertens Res. 2011;34(10):1116–20.PubMedCrossRef
34.
Taherian A-A, Taherian A, Shirvani A. Prevention of preeclampsia with low-dose aspirin or calcium supplementation. Arch Iran Med. 2002;5(3):151–6.
35.
Hauth JC, Goldenberg RL, Parker CR, Philips JB, Copper RL, DuBard MB, et al. Low-dose aspirin therapy to prevent preeclampsia. Am J Obstet Gynecol. 1993;168(4):1083–91. discussion 91‐3.PubMedCrossRef
36.
Sibai BM, Caritis SN, Thom E, Klebanoff M, McNellis D, Rocco L, et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. 1993;329(17):1213–8.PubMedCrossRef
37.
Davies NJ, Gazvani MR, Farquharson RG, Walkinshaw SA. Low-dose aspirin in the prevention of hypertensive disorders of pregnancy in relatively low-risk nulliparous women. Hypertens Pregnancy. 1995;14(1):49–55.CrossRef
38.
Golding J. A randomised trial of low dose aspirin for primiparae in pregnancy. The Jamaica Low Dose Aspirin Study Group. Br J Obstet Gynaecol. 1998;105(3):293–9.PubMedCrossRef
39.
Rotchell YE, Cruickshank JK, Gay MP, Griffiths J, Stewart A, Farrell B, et al. Barbados Low Dose aspirin study in pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications. Br J Obstet Gynaecol. 1998;105(3):286–92.PubMedCrossRef
40.
Subtil D, Goeusse P, Puech F, Lequien P, Biausque S, Breart G, et al. Aspirin (100 mg) used for prevention of pre-eclampsia in nulliparous women: the Essai Régional Aspirine Mère-Enfant study (part 1). BJOG. 2003;110(5):475–84.PubMedCrossRef
41.
Villar J, Papageorghiou AT, Knight HE, Gravett MG, Iams J, Waller SA, et al. The preterm birth syndrome: a prototype phenotypic classification. Am J Obstet Gynecol. 2012;206(2):119–23.PubMedCrossRef
42.
Kramer MS, Papageorghiou A, Culhane J, Bhutta Z, Goldenberg RL, Gravett M, et al. Challenges in defining and classifying the preterm birth syndrome. Am J Obstet Gynecol. 2012;206(2):108–12.PubMedCrossRef
43.
Goldenberg RL, Gravett MG, Iams J, Papageorghiou AT, Waller SA, Kramer M, et al. The preterm birth syndrome: issues to consider in creating a classification system. Am J Obstet Gynecol. 2012;206(2):113–8.PubMedCrossRef
44.
Mone F, Mulcahy C, McParland P, McAuliffe FM. Should we recommend universal aspirin for all pregnant women? Am J Obstet Gynecol. 2017;216(2):141.e1-e5.CrossRef
45.
Mallampati D, Grobman W, Rouse DJ, Werner EF. Strategies for prescribing aspirin to prevent Preeclampsia: a cost-effectiveness analysis. Obstet Gynecol. 2019;134(3):537–44.PubMedCrossRef
46.
Lewkowitz AK, Rouse DJ. Miscommunication about low-dose aspirin for Preeclampsia Prevention-further support for Universal Prophylaxis. JAMA Netw Open. 2021;4(10):e2130960.PubMedCrossRef
47.
Mone F, O’Mahony JF, Tyrrell E, Mulcahy C, McParland P, Breathnach F, et al. Preeclampsia Prevention using Routine Versus Screening Test-indicated aspirin in low-risk women. Hypertension. 2018;72(6):1391–6.PubMedCrossRef
48.
Mather AR, Dom AM, Thorburg LL. Low-dose aspirin in pregnancy: who? When? How much? And why? Curr Opin Obstet Gynecol. 2021;33(2):65–71.PubMedCrossRef
49.
Man R, Hodgetts Morton V, Devani P, Morris RK. Aspirin for preventing adverse outcomes in low risk nulliparous women with singleton pregnancies: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2021;262:105–12.PubMedCrossRef
50.
Hastie R, Tong S, Wikström AK, Sandström A, Hesselman S, Bergman L. Aspirin use during pregnancy and the risk of bleeding complications: a Swedish population-based cohort study. Am J Obstet Gynecol. 2021;224(1):95.e1-e12.CrossRef
51.
Eubanks AA, Nobles CJ, Mumford SL, Kim K, Hill MJ, Decherney AH, et al. The safety of low-dose aspirin on the Mode of Delivery: secondary analysis of the Effect of Aspirin in Gestation and Reproduction Randomized Controlled Trial. Am J Perinatol. 2022;39(6):658–65.PubMedCrossRef
52.
Sutton EF, Hauspurg A, Caritis SN, Powers RW, Catov JM. Maternal outcomes Associated with Lower Range Stage 1 hypertension. Obstet Gynecol. 2018;132(4):843–9.PubMedPubMedCentralCrossRef
53.
Metadata
Title
Low-dose aspirin for the prevention of preterm birth in nulliparous women: systematic review and meta-analysis
Authors
Xin Yan
Wei Zheng
Jia Wang
Xianxian Yuan
Guanghui Li
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Pregnancy and Childbirth / Issue 1/2024
Electronic ISSN: 1471-2393
DOI
https://doi.org/10.1186/s12884-024-06413-2

Other articles of this Issue 1/2024

BMC Pregnancy and Childbirth 1/2024 Go to the issue

Research

Lipids, apolipoproteins and gestational diabetes mellitus: a Mendelian randomization study

Research

Improving health literacy through group antenatal care: results from a cluster randomized controlled trial in Ghana

Research

Association of antenatal corticosteroids with mortality and morbidities in very preterm infants born to women with hypertensive disorders of pregnancy: a multicenter prospective cohort study

Research

Appraising LaQshya’s potential in measuring quality of care for mothers and newborns: a comprehensive review of India’s Labor Room Quality Improvement Initiative

Research

The effect of possible mediators on the association between chewing khat during pregnancy and fetal growth and newborn size at birth in Eastern Ethiopia

Research

Is the surge in cesarean section rates during the COVID-19 pandemic truly substantiated?